ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Cleveland, OH, USA:

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian ....

Enrolling
Serous Ovarian Cancer
Ovarian Cancer
Drug: Fulvestrant
Drug: Regorafenib

Phase 2

Sarah K. Lynam MD

Cleveland, Ohio, United States

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and prima...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Phase 3

Genelux

Cleveland, Ohio, United States and 22 other locations

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 213 other locations

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201)

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Cleveland, Ohio, United States and 46 other locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Cleveland, Ohio, United States and 21 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 176 other locations

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

Phase 2

ImmunoGen
ImmunoGen

Cleveland, Ohio, United States and 77 other locations

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian...

Enrolling
Ovarian Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells
Combination Product: Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

Phase 2

Adaptimmune

Cleveland, Ohio, United States and 28 other locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Cleveland, Ohio, United States and 207 other locations

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...

Active, not recruiting
Ovarian Neoplasms
Drug: Placebo
Drug: Niraparib

Phase 3

Tesaro
Tesaro

Cleveland, Ohio, United States and 194 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems